Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
PD-1–refractory advanced melanoma: how do we get to the finish line?
3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma
Highlights in melanoma from ASCO 2024
Immunotherapy significantly increases the number of patients free from bowel cancer
Encouraging results using mismatched unrelated donors in stem cell transplantation
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy
Importance of MRD in newly developed multiple myeloma
Best practice in HRRm testing in patients with metastatic prostate cancer
ASCO 2024: Lung cancer roundup
Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple myeloma